Status
Global HQ
Taipei, China
Countries of investment
Investment stages
Industries
About
Taho Pharmaceuticals 泰合生技藥品股份有限公司 is a pioneering biotech firm dedicated to the innovative development of novel therapeutics targeting niche medical markets. With a robust portfolio of self-developed products addressing conditions such as schizophrenia, attention deficit hyperactivity disorder (ADHD), and chemotherapy-induced nausea, the company has successfully secured clinical trial permits and patents in the United States. Taho Pharmaceuticals is committed to advancing healthcare solutions through rigorous research and development, aiming to enhance the quality of life for patients with unmet medical needs. Their strategic focus on specialized therapies positions them as a leader in the biotech landscape, driving progress and innovation within the industry.
Taho Pharmaceuticals 泰合生技藥品股份有限公司 is a pioneering biotech firm dedicated to the innovative development of novel therapeutics targeting niche medical markets. With a robust portfolio of self-developed products addressing conditions such as schizophrenia, attention deficit hyperactivity disorder (ADHD), and chemotherapy-induced nausea, the company has successfully secured clinical trial permits and patents in the United States. Taho Pharmaceuticals is committed to advancing healthcare solutions through rigorous research and development, aiming to enhance the quality of life for patients with unmet medical needs. Their strategic focus on specialized therapies positions them as a leader in the biotech landscape, driving progress and innovation within the industry.
Investment Thesis
Manager's Experience
With extensive experience in the healthcare and pharmaceutical sectors, the fund manager has successfully executed over 30 deals across diverse markets, including North America and Europe. Leveraging a data-driven investment approach, they emphasize early-stage opportunities while strategically focusing on transformative technologies. Their adeptness in identifying high-potential companies has resulted in several notable exits, underscoring a robust operator-first philosophy that drives value creation and growth.